ClinicalTrials.gg
RecruitingNCT06146062TRAUMACELLUpdated Oct 16, 2024

Effects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury.

A Phase 2 interventional study of Mesenchymal Stromal Cells (MSC) and placebo in Traumatic Brain Injury, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, none of them phase 3. Brain Injuries, Traumatic · Assistance Publique - Hôpitaux de Paris.

Started
2024
the only one that year
Phase 2
2 of 15
1 open now
Registered
13th of 15
by date

Among the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 2 in phase 2, and was the 13th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

6 of the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Traumatic brain injuries (TBI) are one of the leading causes of death and disability worldwide. These patients are burdened by physical, cognitive, and psychosocial deficits, leading to an important economic impact for society. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. TBI related disability is linked to the severity of the initial injury but also to the following neuroinflammatory response which may persist long after the initial injury.

Moreover, a growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts.

In this context, mesenchymal cell-based therapies are currently investigated to treat various neurological disorders due to their ability to modulate neuroinflammation and to promote simultaneous neurogenesis, angiogenesis, and neuroprotection.

Clinical trials using intravenous MSC have been conducted for various pathologies, all these studies showing a good safety profile.

The hypothesis of the study is that intravenous repeated treatment with MSC derived from Wharton's Jelly of the umbilical cord may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neuroclinical status.

The main objective of the study is to evaluate the effect of iterative IV injections of MSC on post-traumatic neuroinflammation measured in corpus callosum by PET-MRI at 6 months in severe brain injured patients unresponsive to simple verbal commands 5 days after sedation discontinuation.

Read the detailed description

Traumatic brain injuries (TBI) are one of the leading causes of death and disability worldwide. These patients are burdened by physical, cognitive, and psychosocial deficits, leading to an important economic impact for society. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. TBI related disability is linked to the severity of the initial injury but also to the following neuroinflammatory response which may persist long after the initial injury.

Moreover, a growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts.

In this context, mesenchymal cell-based therapies are currently investigated to treat various neurological disorders due to their ability to modulate neuroinflammation and to promote simultaneous neurogenesis, angiogenesis, and neuroprotection. Indeed, several experimental studies have reported that human umbilical cord-derived mesenchymal stromal cells (MSC) have the ability to improve neurological outcomes and recovery in cerebral injury animal models, including TBI.

Clinical trials using intravenous MSC have been conducted for various pathologies, all these studies showing a good safety profile. In TBI, small clinical trials using different modalities for administration of mesenchymal cells are available but none about MSC derived from Wharton's Jelly of the umbilical cord.

The hypothesis of the study is that intravenous repeated treatment with MSC derived from Wharton's Jelly of the umbilical cord may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neuroclinical status.

The main objective of the study is to evaluate the effect of iterative IV injections of MSC on post-traumatic neuroinflammation measured in corpus callosum by PET-MRI at 6 months in severe brain injured patients unresponsive to simple verbal commands 5 days after sedation discontinuation.

03

Conditions studied

  • Traumatic Brain Injury
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

20 healthy volunteers will be included for MRI normalization Volunteer eligibility criteria

Inclusion criteria

Inclusion criteria :

  • Age 18-50 years
  • ASA 1 classification (healthy patient)

Exclusion criteria

Exclusion criteria :

  • Lack of written consent
  • Neurological history likely to alter the image (epilepsy, , meningitis, head trauma)
  • Vulnerable person according to article L1121-6 of the CSP
  • Protected adult person
  • No affiliation to a social security regime
  • Pregnancy
  • for MRI and PET-MRI

    • patients with Pacemaker and defibrillator
    • MR-incompatible prosthetic heart valve
    • Metallic intraocular, intra cerebral or intra medullary foreign bodies
    • Implantable neurostimulation systems
    • Cochlear implants/ear implant
    • Metallic fragments such as bullets, shotgun pellets, and metal shrapnel
    • Cerebral artery aneurysm clips
    • Ventriculo peritoneal shunt with metallic component generating significant artefacts on the MR sequence
    • Catheters with metallic components (Swan-Ganz catheter)
    • Patient unable to remain supine and motionless during the duration of the examination

      68 severe TBI patients with the following inclusion and exclusion criteria will be included"

Patient Inclusion criteria

  • Age 18-50 years
  • Severe TBI defined by:

    • Glasgow score \<12 within the 48 first hours,
    • Brain traumatic lesion on CT scan,
    • Need for intracranial pressure monitoring
  • No other significant organ trauma (AIS \<2)
  • Unresponsive to verbal commands 5 days after sedation discontinuation, for whom, after usual clinical and paraclinical evaluation there has been no decision to interrupt active therapies within 10 days after sedation discontinuation
  • Written consent signed by the close relative

Patient Exclusion criteria

  • History of disease or treatment impairing current or previous year immunity function ( hematologic disease (leukemia, myeloma), viral disease affecting immunity (like ), immunological treatment (corticoid, anti rejection medication, anti TNFα, chemotherapy)
  • History of severe neurological or psychiatric disease likely to alter neurological assessment
  • HTAP > grade III OMS/WHO
  • Ongoing uncontrolled infection with organ failure (septic shock, ARDS) including those due to severe COVID-19
  • \<100 G/L or \<100000/μL, \<8 g/dL, lymphocytes count \<1.5 G/L or 1500 μL , neutrophils count \< 2.5G/L or \<2500/μL, , creatinin > 100 μmol/L
  • Liver function abnormalities (> 2.5mg / dL or transaminases> 5x the ). Patients with Gilbert's disease are eligible if liver tests are normal excluding bilirubinemia
  • Known HIV seropositivity
  • Neoplasia ongoing or treated in the 3 years before screening
  • Bone marrow transplant recipient
  • History of transfusion reaction or
  • Pregnancy
  • Contraindication for MRI and PET-MRI:

    • Patient with Pacemaker and defibrillator
    • MR-incompatible prosthetic heart valve o Metallic intraocular, intra cerebral or intra medullary foreign bodies
    • Implantable neurostimulation systems o Cochlear implants/ ear implant
    • Metallic fragments such as bullets, shotgun pellets, and metal shrapnel
    • Cerebral artery aneurysm clips
    • Ventriculo peritoneal shunt with metallic component generating significant artefacts on the MR sequence
    • Catheters with metallic components (Swan-Ganz catheter)
    • Patient unable to remain supine and motionless during the duration of the examination
  • Participation in another interventional clinical trial of an therapy within 30 days of consent
  • No affiliation to a social security regime
  • Vulnerable person according to article L1121-6 of the CSP
  • Protected adult person
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Intervention

    Final product is a MSC solution at the concentration of 2.10\^6/kg in 150 mL of NaCl 0.9% and human albumin 0.5%, conditioned aseptically and identified for IV administration. 3 injections one week apart.

    Drug: Mesenchymal Stromal Cells (MSC)

  • Placebo comparator
    control

    The placebo will be a solution of NaCl 0.9% 3 injections one week apart.

    Drug: placebo

Interventions

  • DrugMesenchymal Stromal Cells (MSC)

    3 injections one week apart

  • Drugplacebo

    3 injections one week apart

06

What researchers measure

Primary outcomes

  1. effect of iterative IV injections of WJ-UC-MSC on post-traumatic neuroinflammation

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in corpus callosum (Region of Interest, ROI) measured by dynamic PET-MRI

    Time frame: 6 months after the last injection

Secondary outcomes

  1. radiological markers from PET-MRI_1

    The regional fractional anisotropy (FA) from DTI acquisition of PET-MRI

    Time frame: 6 months after the last injection

  2. radiological markers from PET-MRI_2

    The mean diffusibility (MD) from DTI acquisition of PET-MRI

    Time frame: 6 months after the last injection

  3. Treatment feasibility

    number of treatments administrated to the patient

    Time frame: at the third injection

  4. Neurological clinical Score M6

    Glasgow Outcome Scale-Extended

    Time frame: 6 months after the last injection

  5. Neurological clinical Score M12

    Glasgow Outcome Scale-Extended

    Time frame: 12 months after the last injection

  6. cognitive assessment M6

    MOCA scale

    Time frame: 6 months after the last injection

  7. cognitive assessment M12

    MOCA scale

    Time frame: 12 months after the last injection

  8. short term Tolerance D10

    Common Terminology Criteria for Adverse Events

    Time frame: 10 days after the last injection

  9. long term Tolerance M6

    Common Terminology Criteria for Adverse Events

    Time frame: 6 months after the last injection

  10. long term Tolerance M12

    Common Terminology Criteria for Adverse Events

    Time frame: 6 months after the last injection

  11. neuroinflammation of pericontusional

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in pericontusional

    Time frame: 6 months after the last injection

  12. neuroinflammation of grey matter

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in grey matter

    Time frame: 6 months after the last injection

  13. neuroinflammation of white matter

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in white matter

    Time frame: 6 months after the last injection

  14. neuroinflammation of frontal area

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in frontal area

    Time frame: 6 months after the last injection

  15. neuroinflammation of parietal area

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in parietal area

    Time frame: 6 months after the last injection

  16. neuroinflammation of occipital area

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in occipital area

    Time frame: 6 months after the last injection

  17. neuroinflammation of hippocampus

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in hippocampus,

    Time frame: 6 months after the last injection

  18. neuroinflammation of thalamus

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in thalamus,

    Time frame: 6 months after the last injection

  19. neuroinflammation of mesencephalus

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in mesencephalus

    Time frame: 6 months after the last injection

  20. neuroinflammation of cerebellum

    \[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in cerebellum

    Time frame: 6 months after the last injection

  21. Cytokine and chemokine levels in plasma

    Luminex magnetic beads technology

    Time frame: 6 months after the last injection

  22. PBMC profile

    High-dimensional characterization of immune reprogramming during the treatment by single-cell RNA-sequencing of PBMC.

    Time frame: 6 months after the last injection

  23. Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 1.

    H3K27ac

    Time frame: 6 months after the last injection

  24. Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 2.

    H3K4me3

    Time frame: 6 months after the last injection

  25. Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 3.

    ChIP-seq

    Time frame: 6 months after the last injection

  26. Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 4.

    ATAC-seq

    Time frame: 6 months after the last injection

  27. Genome-wide single-nucleotide polymorphism (SNP) genotype.

    DNA sample

    Time frame: After 1 injection

Other outcomes

  1. Analyze the pharmacokinetics and pharmacodynamics of CSM WJ-UC in humans 1

    NGS approach,

    Time frame: After 3rd injection 48 hours later

  2. Analyze the pharmacokinetics and pharmacodynamics of CSM WJ-UC in humans 2

    digital droplet (dd)-PCR approach,

    Time frame: After 3rd injection 48 hours later

  3. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 1

    populations of immune effector cells, such as Tregs,

    Time frame: After 3rd injection 48 hours later

  4. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration.2

    populations of immune effector cells, such as Teff,

    Time frame: After 3rd injection 48 hours later

  5. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration.3

    populations of immune effector cells, such as NK cells,

    Time frame: After 3rd injection 48 hours later

  6. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 4

    populations of immune effector cells, such as NKT,

    Time frame: After 3rd injection 48 hours later

  7. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 5

    populations of immune effector cells, such as MAIT,

    Time frame: After 3rd injection 48 hours later

  8. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 6

    populations of immune effector cells, such as DC

    Time frame: After 3rd injection 48 hours later

  9. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 7

    populations of immune effector cells, such as monocytes

    Time frame: After 3rd injection 48 hours later

  10. Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 8

    populations of immune effector cells, such as B cells.

    Time frame: After 3rd injection 48 hours later

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.

Of 47 phase 2 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 30. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 24, 2023
StartActual
Jun 25, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06146062
Responsible party
Sponsor
First posted
Nov 24, 2023
Start date
Jun 25, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 16, 2024

Study contacts

Vincent Degos
Contact
vincent.degos@aphp.fr
142163761 ext. 33
Stéphanie Sigaut
Contact
stephanie.sigaut@aphp.fr
140875009 ext. 33
Vincent DEGOS
principal investigator · APHP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion